Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968591 | 0.80 | EGLN1 (0.39) | ALDH1A1 | |
| SCHEMBL3622179 | 0.80 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL731664 | 0.76 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL5785545 | 0.76 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL705151 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL515928 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1247297 | 0.75 | TSHR (0.45) | ALDH1A1 | |
| SCHEMBL5069484 | 0.75 | LMNA (0.42) | ALDH1A1 | |
| SCHEMBL10972290 | 0.74 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL1768486 | 0.74 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4335454-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | Hangzhou Grand Biologic Pharmaceutical Inc. (CN) | 2024-03-13 | — | — | EP | claimed |
| US-20230346896-A1 | METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE | HANGZHOU GRAND BIOLOGIC PHARMACEUTICAL INC. (CN) | 2023-11-02 | — | — | US | claimed |
| US-20230346959-A1 | URATE OXIDASE PREPARATION AND USE THEREOF | HANGZHOU GRAND BIOLOGIC PHARMACEUTICAL INC. (CN) | 2023-11-02 | — | — | US | claimed |
| EP-4241841-A1 | METHOD FOR PREPARING POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE | Hangzhou Grand Biologic Pharmaceutical Inc. (CN) | 2023-09-13 | — | — | EP | claimed |
| CN-112839979-A | Method for preparing releasable polymeric reagents | 尼克塔治疗公司 | 2021-05-25 | — | — | CN | claimed |
| EP-2322569-B1 | Polymer derivatives for the selective modification of proteins | AMBRX INC (US) | 2020-08-26 | — | — | EP | claimed |
| US-10550187-B2 | Extra luminal scaffold | INCEPT, LLC (US) | 2020-02-04 | — | — | US | claimed |
| US-20110269974-A1 | Polymer Derivatives | AMBRX, INC. (US) | 2011-11-03 | — | — | US | claimed |
| EP-2322569-A2 | Polymer derivates | AMBRX, INC. (US) | 2011-05-18 | — | — | EP | claimed |
| US-7737226-B2 | Acetylene group-containing poly(alkylene oxide, oxyethylated polyol or olefinic alcohol) | AMBRX, INC. (US) | 2010-06-15 | — | — | US | claimed |
| US-20010044526-A1 | Water soluble polymer backbone such as polyethylene glycol, endcapped with a N-maleimidyl moiety without using a linker; conjugated peptides, proteins, nucleotides and drugs | SHEARWATER CORPORATION | 2001-11-22 | — | — | US | claimed |
| EP-0923566-A4 | HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS | ENZON INC (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2001062827-A2 | N-MALEIMIDYL POLYMER DERIVATIVES | SHEARWATER CORPORATION (US) | 2001-08-30 | — | — | WO | claimed |
| WO-2001000246-A2 | HYDROGELS DERIVED FROM CHITOSAN AND POLY(ETHYLENE GLYCOL) | SHEARWATER CORPORATION (US) | 2001-01-04 | — | — | WO | claimed |
| JP-2000517304-A | — | — | 2000-12-26 | — | — | JP | claimed |
| US-6011042-A | POLYMERIC PRODRUGS ARE PREFERABLY ESTERS OF HYDROXYL-CONTAINING AROMATIC COMPOUNDS AND ARE FORMED BY REACTING A DESIRED AROMATIC, HYDROXYL-CONTAINING COMPOUND WITH A SUBSTANTIALLY NON-ANTIGENIC POLYMER | ENZON, INC. (US) | 2000-01-04 | — | — | US | claimed |
| US-5965566-A | A WATER SOLUBLE BIOLOGICAL ACTIVE DRUG CONJUGATED WITH POLYOXYETHYLENE GLYCOL THROUGH A HYDROLYZABLE ESTER LINKAGING SPACER; CONTROLLED RELEASE PROPERTIES | ENZON, INC. (US) | 1999-10-12 | — | — | US | claimed |
| EP-0923566-A1 | HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS | ENZON, INC. (US) | 1999-06-23 | — | — | EP | claimed |
| WO-1998007713-A1 | HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS | ENZON, INC. (US) | 1998-02-26 | — | — | WO | claimed |
| EP-0295073-B1 | Chromatographic material | CHROMATOCHEM INC (US) | 1997-03-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269974-A1 | Polymer Derivatives | ASNS, PHAX, GRAMD1A | ALDH1A1 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.